{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:15:06Z","timestamp":1783646106804,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113414"],"award-info":[{"award-number":["70113414"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113414"],"award-info":[{"award-number":["70113414"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113414"],"award-info":[{"award-number":["70113414"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["2024.20"],"award-info":[{"award-number":["2024.20"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493872418"],"award-info":[{"award-number":["493872418"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493872418"],"award-info":[{"award-number":["493872418"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493872418"],"award-info":[{"award-number":["493872418"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Very high-risk neuroblastoma is induction-refractory and often harbors mutations in RAS and\/or p53 signaling combined with telomere maintenance mechanisms. Event-free survival is &lt;20% in these children. Patients unable to mobilize sufficient hematopoietic stem cells to harvest for busulfan\/melphalan-based high-dose chemotherapy before autologous transplantation are also at high risk for relapse. Haploidentical stem cell transplantation (haplo-SCT), offering graft-versus-tumor effects and enhanced antibody-dependent cellular cytotoxicity, has emerged as a feasible treatment. We report administration of a conditioning regimen combining myeloablative busulfan\/melphalan anti-tumor therapy with the immunological advantages of haplo-SCT and GD2-directed antibody-based immunotherapy with dinutuximab beta (DB). A 5-patient pilot cohort was treated with systemic induction (salvage) therapy and local therapy per national guidelines. Prior to busulfan, melphalan, fludarabine and antithymocyte globulin conditioning followed by T\/B-cell-depleted haplo-SCT and 6 DB cycles, 2 patients received [\n                    <jats:sup>131<\/jats:sup>\n                    I]MIBG therapy. All patients were successfully engrafted. Three of five patients are alive and have remained in first complete remission for 7.3, 6.3 and 1.5 years after haplo-SCT, while two patients experienced events (one relapse, one non-relapse death). Primary busulfan-based haplo-SCT combined with DB immunotherapy was feasible and effective. Early results suggest a survival benefit for these pediatric patient subgroups at very high risk. Confirmation in a larger controlled trial is warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-02912-2","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:11:52Z","timestamp":1780063912000},"page":"926-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma"],"prefix":"10.1038","volume":"61","author":[{"given":"Sveva","family":"Castelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-9941","authenticated-orcid":false,"given":"Tim","family":"Flaadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Thole-Kliesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-4841","authenticated-orcid":false,"given":"Felix","family":"Zirngibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6828-1783","authenticated-orcid":false,"given":"Lena","family":"Oevermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-5412","authenticated-orcid":false,"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Astrahantseff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-8451","authenticated-orcid":false,"given":"Thorsten","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-890X","authenticated-orcid":false,"given":"Barbara","family":"Hero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hundsdoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian M. M.","family":"Rogasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-2142","authenticated-orcid":false,"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Warmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-1201","authenticated-orcid":false,"given":"Johannes H.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Eggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-4893","authenticated-orcid":false,"given":"Hedwig E.","family":"Deubzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2912_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","volume":"27","author":"T Monclair","year":"2009","unstructured":"Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298\u2013303. https:\/\/doi.org\/10.1200\/JCO.2008.16.6876.","journal-title":"J Clin Oncol"},{"key":"2912_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","volume":"27","author":"SL Cohn","year":"2009","unstructured":"Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289\u201397. https:\/\/doi.org\/10.1200\/JCO.2008.16.6785.","journal-title":"J Clin Oncol"},{"key":"2912_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.78","volume":"2","author":"KK Matthay","year":"2016","unstructured":"Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078. https:\/\/doi.org\/10.1038\/nrdp.2016.78.","journal-title":"Nat Rev Dis Primers"},{"key":"2912_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/bjc.2016.302","volume":"115","author":"NO Basta","year":"2016","unstructured":"Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048\u201357. https:\/\/doi.org\/10.1038\/bjc.2016.302.","journal-title":"Br J Cancer"},{"key":"2912_CR5","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/cncr.30934","volume":"123","author":"WB London","year":"2017","unstructured":"London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials. Cancer. 2017;123:4914\u201323. https:\/\/doi.org\/10.1002\/cncr.30934.","journal-title":"Cancer"},{"key":"2912_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/pbc.26192","volume":"64","author":"L Moreno","year":"2017","unstructured":"Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC\/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017;64:25\u201331. https:\/\/doi.org\/10.1002\/pbc.26192","journal-title":"Pediatr Blood Cancer"},{"key":"2912_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nature14980","volume":"526","author":"M Peifer","year":"2015","unstructured":"Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700\u20134. https:\/\/doi.org\/10.1038\/nature14980","journal-title":"Nature"},{"key":"2912_CR8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/ng.3438","volume":"47","author":"LJ Valentijn","year":"2015","unstructured":"Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47:1411\u20134. https:\/\/doi.org\/10.1038\/ng.3438.","journal-title":"Nat Genet"},{"key":"2912_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2529","volume":"45","author":"TJ Pugh","year":"2013","unstructured":"Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45:279\u201384. https:\/\/doi.org\/10.1038\/ng.2529.","journal-title":"Nat Genet"},{"key":"2912_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3349","volume":"47","author":"A Schramm","year":"2015","unstructured":"Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47:872\u20137. https:\/\/doi.org\/10.1038\/ng.3349","journal-title":"Nat Genet"},{"key":"2912_CR11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aat6768","volume":"362","author":"S Ackermann","year":"2018","unstructured":"Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362:1165\u201370. https:\/\/doi.org\/10.1126\/science.aat6768.","journal-title":"Science"},{"key":"2912_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.20517\/cdr.2019.009","volume":"2","author":"ER Tucker","year":"2019","unstructured":"Tucker ER, Poon E, Chesler L. Targeting MYCN and ALK in resistant and relapsing neuroblastoma. Cancer Drug Resist. 2019;2:803\u201312. https:\/\/doi.org\/10.20517\/cdr.2019.009.","journal-title":"Cancer Drug Resist"},{"key":"2912_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ccr.2012.02.010","volume":"21","author":"S Zhu","year":"2012","unstructured":"Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012;21:362\u201373. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.010.","journal-title":"Cancer Cell"},{"key":"2912_CR14","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","volume":"118","author":"LB To","year":"2011","unstructured":"To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530\u201340. https:\/\/doi.org\/10.1182\/blood-2011-06-318220.","journal-title":"Blood"},{"key":"2912_CR15","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.22.01630","volume":"41","author":"T Flaadt","year":"2023","unstructured":"Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnard\u00f3ttir HB, Poetschger U, et al. Anti-GD2 antibody dinutuximab beta and low-dose interleukin 2 after haploidentical stem-cell transplantation in patients with relapsed neuroblastoma: a multicenter, phase I\/II trial. J Clin Oncol. 2023;41:3135\u201348. https:\/\/doi.org\/10.1200\/JCO.22.01630","journal-title":"J Clin Oncol"},{"key":"2912_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2017.12.805","volume":"24","author":"T Illhardt","year":"2018","unstructured":"Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, et al. Haploidentical stem cell transplantation for refractory\/relapsed neuroblastoma. Biol Blood Marrow Transpl. 2018;24:1005\u201312. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.805","journal-title":"Biol Blood Marrow Transpl"},{"key":"2912_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690467","volume":"12","author":"CM Seitz","year":"2021","unstructured":"Seitz CM, Flaadt T, Mezger M, Lang AM, Michaelis S, Katz M, et al. Immunomonitoring of stage IV relapsed neuroblastoma patients undergoing haploidentical hematopoietic stem cell transplantation and subsequent GD2 (ch14.18\/CHO) antibody treatment. Front Immunol. 2021;12:690467. https:\/\/doi.org\/10.3389\/fimmu.2021.690467.","journal-title":"Front Immunol"},{"key":"2912_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein R, Potschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500\u201314. https:\/\/doi.org\/10.1016\/S1470-2045(17)30070-0.","journal-title":"Lancet Oncol"},{"key":"2912_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001. e381.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2912_CR20","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2912_CR21","doi-asserted-by":"publisher","unstructured":"Szymansky A, Kruetzfeldt LM, Heukamp LC, Hertwig F, Theissen J, Deubzer HE et al. Neuroblastoma risk assessment and treatment stratification with hybrid capture-based panel sequencing. J Pers Med 2021; 11. https:\/\/doi.org\/10.3390\/jpm11080691","DOI":"10.3390\/jpm11080691"},{"key":"2912_CR22","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35:2580\u20137. https:\/\/doi.org\/10.1200\/JCO.2016.72.0177","journal-title":"J Clin Oncol"},{"key":"2912_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/pbc.23132","volume":"58","author":"S Modak","year":"2012","unstructured":"Modak S, Cheung IY, Kushner BH, Kramer K, Reich L, Cheung NK. Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer. 2012;58:469\u201371. https:\/\/doi.org\/10.1002\/pbc.23132.","journal-title":"Pediatr Blood Cancer"},{"key":"2912_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/a-2556-4302","volume":"237","author":"T Simon","year":"2025","unstructured":"Simon T, Thole T, Castelli S, Timmermann B, Jazmati D, Schwarz R, et al. GPOH guidelines for diagnosis and first-line treatment of patients with neuroblastic tumors, update 2025. Klin Padiatr. 2025;237:117\u201340. https:\/\/doi.org\/10.1055\/a-2556-4302.","journal-title":"Klin Padiatr"},{"key":"2912_CR25","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1200\/JCO.20.00203","volume":"38","author":"R Mody","year":"2020","unstructured":"Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2020;38:2160\u20139. https:\/\/doi.org\/10.1200\/JCO.20.00203.","journal-title":"J Clin Oncol"},{"key":"2912_CR26","doi-asserted-by":"publisher","unstructured":"Gray JC, Weston R, Owens C, Canete A, Gambart M, De Wilde B, et al. Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON immuno phase II trial. J Clin Oncol 2025 https:\/\/doi.org\/10.1200\/JCO-25-01868","DOI":"10.1200\/JCO-25-01868"},{"key":"2912_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.32080","volume":"72","author":"C Pasqualini","year":"2025","unstructured":"Pasqualini C, Proust S, Schleiermacher G, Gambart M, Jannier S, Petit A, et al. Chemo-immunotherapy rescue for high-risk neuroblastoma patients with progressive disease before high-dose chemotherapy: real-world data from the SACHA-France study. Pediatr Blood Cancer. 2025;72:e32080. https:\/\/doi.org\/10.1002\/pbc.32080.","journal-title":"Pediatr Blood Cancer"},{"key":"2912_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/00000421-199206000-00009","volume":"15","author":"RJ Hutchinson","year":"1992","unstructured":"Hutchinson RJ, Sisson JC, Shapiro B, Miser JS, Normole D, Shulkin BL, et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol. 1992;15:226\u201332. https:\/\/doi.org\/10.1097\/00000421-199206000-00009.","journal-title":"Am J Clin Oncol"},{"key":"2912_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/mpo.2950190203","volume":"19","author":"T Klingebiel","year":"1991","unstructured":"Klingebiel T, Berthold F, Treuner J, Schwabe D, Fischer M, Feine U, et al. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol. 1991;19:84\u201388. https:\/\/doi.org\/10.1002\/mpo.2950190203.","journal-title":"Med Pediatr Oncol"},{"key":"2912_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.1992.10.12.1889","volume":"10","author":"LS Lashford","year":"1992","unstructured":"Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, et al. Phase I\/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children\u2019s Cancer Study Group investigation. J Clin Oncol. 1992;10:1889\u201396. https:\/\/doi.org\/10.1200\/JCO.1992.10.12.1889.","journal-title":"J Clin Oncol"},{"key":"2912_CR31","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526\u2013e536. https:\/\/doi.org\/10.1016\/S2352-3026(16)30114-4","journal-title":"Lancet Haematol"},{"key":"2912_CR32","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","volume":"59","author":"V Domingos","year":"2024","unstructured":"Domingos V, Nezvalova-Henriksen K, Dadkhah A, Moreno-Martinez ME, Ben Hassine K, Pires V, et al. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2024;59:1641\u201353. https:\/\/doi.org\/10.1038\/s41409-024-02413-0.","journal-title":"Bone Marrow Transpl"},{"key":"2912_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41409-021-01551-z","volume":"57","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Eyrich M, Mielke S, Meisel R, Niederwieser D, Schlegel PG, et al. Results of a multicenter phase I\/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transpl. 2022;57:423\u201330. https:\/\/doi.org\/10.1038\/s41409-021-01551-z.","journal-title":"Bone Marrow Transpl"},{"key":"2912_CR34","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41591-023-02297-5","volume":"29","author":"KC Goldsmith","year":"2023","unstructured":"Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023;29:1092\u2013102. https:\/\/doi.org\/10.1038\/s41591-023-02297-5.","journal-title":"Nat Med"},{"key":"2912_CR35","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","volume":"22","author":"M Fischer","year":"2021","unstructured":"Fischer M, Moreno L, Ziegler DS, Marshall LV, Zwaan CM, Irwin MS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021;22:1764\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(21)00536-2.","journal-title":"Lancet Oncol"},{"key":"2912_CR36","doi-asserted-by":"publisher","unstructured":"Klingel L, Siebert N, Troschke-Meurer S, Zumpe M, Ehlert K, Huber, S et al. Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: results from compassionate-use treatments. Cancers. 2022; 14 https:\/\/doi.org\/10.3390\/cancers14235802","DOI":"10.3390\/cancers14235802"},{"key":"2912_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","volume":"15","author":"M Schumm","year":"2013","unstructured":"Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, et al. Depletion of T-cell receptor alpha\/beta and CD19-positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013;15:1253\u20138. https:\/\/doi.org\/10.1016\/j.jcyt.2013.05.014.","journal-title":"Cytotherapy"},{"key":"2912_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31845","volume":"72","author":"W Wei","year":"2025","unstructured":"Wei W, Fader ME, Kushner BH, Cardenas FI, Kramer K, Basu E, et al. Pulmonary toxicity associated with concurrent lorlatinib and anti-gd2 monoclonal antibody therapy in patients with neuroblastoma. Pediatr Blood Cancer. 2025;72:e31845. https:\/\/doi.org\/10.1002\/pbc.31845.","journal-title":"Pediatr Blood Cancer"},{"key":"2912_CR39","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","volume":"19","author":"R Ladenstein","year":"2018","unstructured":"Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(18)30578-3.","journal-title":"Lancet Oncol"},{"key":"2912_CR40","doi-asserted-by":"publisher","first-page":"e1343775","DOI":"10.1080\/2162402X.2017.1343775","volume":"6","author":"N Siebert","year":"2017","unstructured":"Siebert N, Zumpe M, Juttner M, Troschke-Meurer S, Lode HN. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD(2) antibody ch14.18\/CHO. Oncoimmunology. 2017;6:e1343775 https:\/\/doi.org\/10.1080\/2162402X.2017.1343775.","journal-title":"Oncoimmunology"},{"key":"2912_CR41","unstructured":"Gray, J.C. Data from the MiNivAn trial, in ANR 2025 Conference Paper. 2025: Washington DC."},{"key":"2912_CR42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388:1284\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2210859.","journal-title":"N Engl J Med"},{"key":"2912_CR43","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","volume":"30","author":"L Fischer-Riepe","year":"2024","unstructured":"Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, et al. Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clin Cancer Res. 2024;30:3564\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3157.","journal-title":"Clin Cancer Res"},{"key":"2912_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, et al. GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD(2) and releasing inducible IL-18. Front Immunol. 2022;13:839783. https:\/\/doi.org\/10.3389\/fimmu.2022.839783.","journal-title":"Front Immunol"},{"key":"2912_CR45","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2019.11642","volume":"322","author":"JR Park","year":"2019","unstructured":"Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322:746\u201355. https:\/\/doi.org\/10.1001\/jama.2019.11642.","journal-title":"JAMA"},{"key":"2912_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349783","volume":"42","author":"SG DuBois","year":"2022","unstructured":"DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book. 2022;42:1\u201313. https:\/\/doi.org\/10.1200\/EDBK_349783.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2912_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat Med. 2025;31:849\u201360. https:\/\/doi.org\/10.1038\/s41591-024-03449-x.","journal-title":"Nat Med"},{"key":"2912_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","volume":"33","author":"L Nguyen","year":"2004","unstructured":"Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety\/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transpl. 2004;33:979\u201387. https:\/\/doi.org\/10.1038\/sj.bmt.1704446.","journal-title":"Bone Marrow Transpl"},{"key":"2912_CR49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","volume":"51","author":"IH Bartelink","year":"2012","unstructured":"Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331\u201345. https:\/\/doi.org\/10.2165\/11598180-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"2912_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","volume":"60","author":"R Lawson","year":"2021","unstructured":"Lawson R, Staatz CE, Fraser CJ, Hennig S. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet. 2021;60:17\u201351.","journal-title":"Clin Pharmacokinet"},{"key":"2912_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28603","volume":"67","author":"V Poinsignon","year":"2020","unstructured":"Poinsignon V, Faivre L, Nguyen L, Neven B, Broutin S, Moshous D, et al. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning. Pediatr Blood Cancer. 2020;67:e28603.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02912-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02912-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02912-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:02:48Z","timestamp":1783645368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02912-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02912-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TS has received funding in the form of institutional payments from the German Childhood Cancer Foundation and consulting fees from Recordati Rare Diseases, Norgine Ltd., Amgen, and Merck KGaA. TF, PL, AE and HED have worked as consultants of Recordati Rare Diseases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}